Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs 10X Genomics Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while 10X Genomics Inc trades at $42.5 (market cap $5.43B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.3× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TXG | |
|---|---|---|
Market Cap | $39.89B | $5.43B |
Sector | Health | Health |
52-Week High | $491.22 | $43.10 |
52-Week Low | $278.09 | $11.34 |
Enterprise Value | $38.15B | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TXG trades at $42.73, down 0.86% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth and beat EPS estimates, with net losses narrowing significantly from -$166M in 2022 to -$44M in 2025. Recent collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics highlight strategic expansion in diagnostics and multiomics capabilities.
Outlook remains cautiously optimistic as improving margins and cash flow support growth, but high valuation multiples and persistent net losses pose risks. Analyst consensus is mixed with a $35.14 price target below current levels, suggesting limited near-term upside despite positive operational trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
